VHL and nonpapillary renal cell carcinoma: Emerging strategies exploit these interdependencies: glutaminase inhibitors potentiate ferroptosis in SLC7A11-high tumors, while mTORC1/2 dual antagonists overcome compensatory lipid scavenging in VHL-mutant ccRCC [51, 52].